Primary Biliary Cholangitis
AASLD develops evidence-based practice guidelines and practice guidances which are updated regularly by a multi-disciplinary panel of experts, including hepatologists, and include recommendations of preferred approaches to the diagnostic, therapeutic, and preventive aspects of care.
Practice Guideline
AASLD AGA clinical Practice Guideline on management of primary biliary cholangitis
AASLD and AGA have jointly developed an evidence-based guideline for primary biliary cholangitis (PBC), evaluating newer treatment options and providing recommendations for diagnosis and management. The guideline addresses key clinical challenges, including diagnosis in patients with less common antibody profiles, treatment escalation, and management of PBC-related itching.
Practice Guidance
Guidance on Primary Biliary Cholangitis [updated November 2018]
Primary Biliary Cholangitis (PBC) is considered an autoimmune disease because of its hallmark serologic signature, antimitochondrial antibody (AMA), and specific bile duct pathology. The etiology of PBC is thought to be due to a combination of genetic risk factors and environmental triggers.
Primary Biliary Cholangitis: 2021 Practice Guidance Update
The AASLD 2021 Practice Guidance on Primary Biliary Cholangitis (PBC) is a focused update of the PBC guidance published in 2018. The major changes from the last guidance to this guidance include information about obeticholic acid (OCA).